Theratechnologies Stock Price, News & Analysis (TSE:TH) C$2.20 +0.05 (+2.33%) (As of 12/1/2023 ET) Add Compare Share Share Today's RangeC$2.08▼C$2.2450-Day RangeC$1.27▼C$2.9052-Week RangeC$1.22▼C$7.96Volume15,537 shsAverage Volume41,127 shsMarket CapitalizationC$100.80 millionP/E RatioN/ADividend Yield3.76%Price TargetC$5.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider Trades Theratechnologies MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside150.0% UpsideC$5.50 Price TargetShort InterestN/ADividend StrengthWeakBased on Four FactorsSustainabilityN/ANews SentimentN/AInsider TradingAcquiring SharesC$91,707 Bought Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.81 out of 5 stars 3.3 Analyst's Opinion Consensus RatingTheratechnologies has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of C$5.50, Theratechnologies has a forecasted upside of 150.0% from its current price of C$2.20.Amount of Analyst CoverageTheratechnologies has only been the subject of 1 research reports in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for TH. Previous Next 1.7 Dividend Strength Dividend LeadershipTheratechnologies is a leading dividend payer. It pays a dividend yield of 3.76%, putting its dividend yield in the top 25% of dividend-paying stocks.Dividend GrowthTheratechnologies does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TH. Previous Next 0.6 News and Social Media Coverage Search Interest10 people have searched for TH on MarketBeat in the last 30 days. This is an increase of 233% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Theratechnologies insiders have bought more of their company's stock than they have sold. Specifically, they have bought C$91,707.00 in company stock and sold C$0.00 in company stock.Percentage Held by Insiders10.47% of the stock of Theratechnologies is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 28.60% of the stock of Theratechnologies is held by institutions. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Theratechnologies is -1.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Theratechnologies is -1.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioDue to a projected decrease in earnings for Theratechnologies, their PEG ratio cannot be calculated. Previous Next See Top Rated MarketRank™ Stocks Here About Theratechnologies Stock (TSE:TH)Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, a recombinant humanized monoclonal antibody, which is an injection for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; and TH1902, which is in Phase 1 clinical trials for the treatment of various solid tumors, including HR+ breast cancer, triple negative breast cancer, ovarian cancer, endometrial cancer, melanoma, thyroid cancer, small cell lung cancer, and prostate cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.Read More TH Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TH Stock News HeadlinesNovember 24, 2023 | finance.yahoo.comTheratechnologies Receives 2023 CQDM ADRIQ RSRI Innovation AwardNovember 2, 2023 | msn.comTheratechnologies (THTX) Price Target Increased by 16.41% to 5.54December 3, 2023 | Wealthpress (Ad)Trading Experts Call It “The Perfect Tesla Trade”Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.October 26, 2023 | msn.comTheratechnologies prices its public offering; shares plummetOctober 26, 2023 | msn.comWhy Is Theratechnologies (THTX) Stock Down 22% Today?October 25, 2023 | msn.comTheratechnologies proposes stock offering, private placementOctober 25, 2023 | finance.yahoo.comTheratechnologies Announces Proposed Public Offering of Common Shares and Concurrent Private PlacementOctober 21, 2023 | theglobeandmail.comTheratechnologies: Top 10 Undervalued Growth Stocks on TSX (TH)December 3, 2023 | DTI Trader (Ad)All the trading advice you’ve ever received boils down to thisAll the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.October 14, 2023 | msn.comTheratechnologies doses first subject in ovarian cancer trialOctober 13, 2023 | finance.yahoo.comTheratechnologies Announces Results from Trogarzo® (Ibalizumab-uiyk) Intramuscular Administration StudyOctober 13, 2023 | finance.yahoo.comTheratechnologies Presents Data at ID Week Showing Tesamorelin Reduces Visceral Adipose Tissue (VAT) and Liver Fat in People with HIV on Integrase Inhibitors (INSTIs)September 26, 2023 | markets.businessinsider.comTheratechnologies: A Buy Rating Backed by Financial Stability, Clinical Progress, and Underappreciated Value OpportunitiesSeptember 26, 2023 | finance.yahoo.comMorning News Call - Canada, September 26September 26, 2023 | marketwatch.comTheratechnologies Warns of Going Concern UncertaintySeptember 26, 2023 | marketwatch.comToronto Stocks Down; Theratechnologies Falls After Going Concern WarningSeptember 26, 2023 | finance.yahoo.comTheratechnologies Reports Financial Results for the Third Quarter and Nine Months of Fiscal 2023 and Provides Business UpdatesSeptember 26, 2023 | sfgate.comTheratechnologies: Fiscal Q3 Earnings SnapshotSeptember 26, 2023 | finance.yahoo.comTheratechnologies Reports Financial Results for the Third Quarter and Nine Months of Fiscal 2023 and Provides Business UpdatesSeptember 20, 2023 | finance.yahoo.comTheratechnologies to Present at the Cantor Fitzgerald Global Healthcare Conference 2023September 18, 2023 | finance.yahoo.comTheratechnologies to Announce Third Quarter 2023 Financial Results and Provide Business UpdateSeptember 5, 2023 | finance.yahoo.comTheratechnologies Announces Certain Preliminary Q3 2023 Financial HighlightsAugust 25, 2023 | theglobeandmail.comClosing Bell: Theratechnologies down on Thursday (TH)August 21, 2023 | finance.yahoo.comToronto Stock Exchange, Theratechnologies Inc., View From The C-SuiteAugust 21, 2023 | theglobeandmail.comTheratechnologies: Top 25 Undervalued Toronto Stock Exchange Stocks (TH)August 5, 2023 | theglobeandmail.comClosing Bell: Theratechnologies 5.75 Pct Debs up on Tuesday (TH-DB-U)August 2, 2023 | msn.comTheratechnologies (THTX) Price Target Increased by 169.59% to 7.62See More Headlines Receive TH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Theratechnologies and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings9/26/2023Today12/02/2023Next Earnings (Estimated)2/27/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeTSE Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolTSE:TH CUSIPN/A CIKN/A Webwww.theratech.com Phone+1-514-3367800FaxN/AEmployees144Year FoundedN/APrice Target and Rating Average Stock Price TargetC$5.50 High Stock Price TargetC$5.50 Low Stock Price TargetC$5.50 Potential Upside/Downside+150.0%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)C($1.68) Trailing P/E RatioN/A Forward P/E Ratio54.02 P/E Growth-8.5Net IncomeC$-29,130,000.00 Net Margins-36.54% Pretax MarginN/A Return on Equity-1,116.86% Return on Assets-9.78% Debt Debt-to-Equity Ratio562.07 Current Ratio0.41 Quick Ratio0.64 Sales & Book Value Annual SalesC$79.73 million Price / Sales1.26 Cash FlowC$0.59 per share Price / Cash Flow3.76 Book ValueC($1.72) per share Price / Book-1.28Miscellaneous Outstanding Shares45,820,000Free FloatN/AMarket CapC$100.80 million OptionableNot Optionable Beta1.30 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for December 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Paul Lévesque (Age 59)President, CEO & Director Comp: $1.81MMr. Philippe Dubuc M.B.A. (Age 56)MBA, Senior VP & CFO Comp: $620.85kMr. Jocelyn Lafond L.L.M. (Age 55)LL.B., General Counsel & Corporate Secretary Comp: $449.82kDr. Christian Marsolais Ph.D. (Age 60)Senior VP & Chief Medical Officer Comp: $644.38kMr. John Leasure (Age 58)Global Commercial Officer Comp: $709.45kHon. Andre Dupras M.Sc. (Age 59)Vice President of Human Resources More ExecutivesKey CompetitorsScythian BiosciencesCVE:SCYB138267 (COM.TO)TSE:COMNovoheartCVE:NVHBriaCell TherapeuticsTSE:BCTIntelGenx TechnologiesCVE:IGXView All CompetitorsInsidersDale WeilBought 36,200 shares on 11/1/2023Total: C$49,956.00 ($1.38/share)Joseph ArenaBought 10,000 shares on 10/30/2023Total: C$9,250.00 ($0.93/share)Dawn SvoronosBought 15,800 shares on 10/27/2023Total: C$21,646.00 ($1.37/share)Philippe DubucBought 8,000 shares on 10/27/2023Total: C$10,855.20 ($1.36/share)View All Insider Transactions TH Stock Analysis - Frequently Asked Questions Should I buy or sell Theratechnologies stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Theratechnologies in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" TH shares. View TH analyst ratings or view top-rated stocks. What is Theratechnologies' stock price target for 2024? 2 analysts have issued 1 year target prices for Theratechnologies' stock. Their TH share price targets range from C$5.50 to C$5.50. On average, they predict the company's stock price to reach C$5.50 in the next twelve months. This suggests a possible upside of 150.0% from the stock's current price. View analysts price targets for TH or view top-rated stocks among Wall Street analysts. How have TH shares performed in 2023? Theratechnologies' stock was trading at C$1.20 at the beginning of 2023. Since then, TH stock has increased by 83.3% and is now trading at C$2.20. View the best growth stocks for 2023 here. When is Theratechnologies' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024. View our TH earnings forecast. How were Theratechnologies' earnings last quarter? Theratechnologies Inc. (TSE:TH) posted its quarterly earnings data on Tuesday, September, 26th. The company reported ($0.04) earnings per share (EPS) for the quarter. The firm had revenue of $27.81 million for the quarter. Theratechnologies had a negative net margin of 36.54% and a negative trailing twelve-month return on equity of 1,116.86%. What other stocks do shareholders of Theratechnologies own? Based on aggregate information from My MarketBeat watchlists, some companies that other Theratechnologies investors own include Stars Group (TSGI), BCE (BCE), ProMetic Life Sciences (PLI), Teranga Gold (TGZ), Nemaska Lithium (NMX), Shopify (SHOP), United Therapeutics (UTHR) and Avigilon (AVO). How do I buy shares of Theratechnologies? Shares of TH stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. This page (TSE:TH) was last updated on 12/3/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Theratechnologies Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.